Hellerup, Denmark

Mads Jellingsoe

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2021-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mads Jellingsoe: Innovator in Niclosamide Formulations

Introduction

Mads Jellingsoe is a notable inventor based in Hellerup, Denmark. He has made significant contributions to the field of pharmaceutical formulations, particularly in the treatment of viral infections. With a total of two patents to his name, Jellingsoe is recognized for his innovative approaches to addressing pressing health challenges.

Latest Patents

Jellingsoe's latest patents focus on niclosamide formulations for treating diseases associated with SARS-CoV-2. The inventions detail a method of treating viral infections by administering a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, along with a cyclodextrin. This method can be administered by inhalation, intraorally, and/or intranasally, showcasing a novel approach to combating viral infections.

Career Highlights

Mads Jellingsoe is currently associated with Union Therapeutics A/S, where he continues to develop innovative solutions in the pharmaceutical industry. His work is pivotal in advancing treatment options for viral infections, particularly in the context of the ongoing global health crisis.

Collaborations

Some of Jellingsoe's notable coworkers include Morten Otto Alexander Sommer and Rasmus Vendler Toft-Kehler. Their collaborative efforts contribute to the innovative environment at Union Therapeutics A/S.

Conclusion

Mads Jellingsoe stands out as an influential inventor in the realm of pharmaceutical innovations. His work on niclosamide formulations represents a significant advancement in the treatment of viral infections, particularly those caused by SARS-CoV-2.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…